New mutation in the β1 propeller domain of LRP4 responsible for congenital myasthenic syndrome associated with Cenani-Lenz syndrome.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 08 2023
28 08 2023
Historique:
received:
03
04
2023
accepted:
20
08
2023
medline:
31
8
2023
pubmed:
29
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Congenital myasthenic syndromes (CMS) are a clinically and genetically heterogeneous group of rare diseases due to mutations in neuromuscular junction (NMJ) protein-coding genes. Until now, many mutations encoding postsynaptic proteins as Agrin, MuSK and LRP4 have been identified as responsible for increasingly complex CMS phenotypes. The majority of mutations identified in LRP4 gene causes bone diseases including CLS and sclerosteosis-2 and rare cases of CMS with mutations in LRP4 gene has been described so far. In the French cohort of CMS patients, we identified a novel LRP4 homozygous missense mutation (c.1820A > G; p.Thy607Cys) within the β1 propeller domain in a patient presenting CMS symptoms, including muscle weakness, fluctuating fatigability and a decrement in compound muscle action potential in spinal accessory nerves, associated with congenital agenesis of the hands and feet and renal malformation. Mechanistic expression studies show a significant decrease of AChR aggregation in cultured patient myotubes, as well as altered in vitro binding of agrin and Wnt11 ligands to the mutated β1 propeller domain of LRP4 explaining the dual phenotype characterized clinically and electoneuromyographically in the patient. These results expand the LRP4 mutations spectrum associated with a previously undescribed clinical association involving impaired neuromuscular transmission and limb deformities and highlighting the critical role of a yet poorly described domain of LRP4 at the NMJ. This study raises the question of the frequency of this rare neuromuscular form and the future diagnosis and management of these cases.
Identifiants
pubmed: 37640745
doi: 10.1038/s41598-023-41008-5
pii: 10.1038/s41598-023-41008-5
pmc: PMC10462681
doi:
Substances chimiques
Agrin
0
LRP4 protein, human
0
LDL-Receptor Related Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14054Informations de copyright
© 2023. Springer Nature Limited.
Références
Sci Rep. 2020 Mar 11;10(1):4524
pubmed: 32161296
Physiol Rev. 2015 Jul;95(3):809-52
pubmed: 26109340
J Biol Chem. 2011 Nov 25;286(47):40624-30
pubmed: 21969364
Neurol Genet. 2020 Dec 03;6(6):e534
pubmed: 33659639
Annu Rev Biochem. 2006;75:655-80
pubmed: 16756506
Am J Med Genet A. 2019 Feb;179(2):266-279
pubmed: 30569497
Mol Brain. 2012 Feb 06;5:7
pubmed: 22309736
Acta Myol. 2005 Oct;24(2):55-9
pubmed: 16550915
FEBS Lett. 2012 Aug 14;586(17):2648-61
pubmed: 22709956
Hum Mutat. 2018 Jun;39(6):811-815
pubmed: 29524275
PLoS One. 2015 Feb 17;10(2):e0116701
pubmed: 25688974
Skelet Muscle. 2011 Nov 01;1:34
pubmed: 22040608
Brain. 2014 Sep;137(Pt 9):2429-43
pubmed: 24951643
Am J Hum Genet. 2010 May 14;86(5):696-706
pubmed: 20381006
Am J Hum Genet. 2009 Aug;85(2):155-67
pubmed: 19631309
Am J Med Genet A. 2013 Jun;161A(6):1475-9
pubmed: 23636941
Hum Mol Genet. 2005 Nov 15;14(22):3523-38
pubmed: 16207730
Hum Mol Genet. 2014 Apr 1;23(7):1856-68
pubmed: 24234652
J Cell Biol. 2004 May 24;165(4):505-15
pubmed: 15159418
JAMA Neurol. 2015 Aug;72(8):889-96
pubmed: 26052878
Development. 2006 Dec;133(24):4993-5000
pubmed: 17119023
J Hum Genet. 2022 May;67(5):253-259
pubmed: 34857885
Int J Mol Sci. 2018 Jun 05;19(6):
pubmed: 29874875
Cell Mol Life Sci. 2013 Sep;70(17):3077-88
pubmed: 23178848
J Clin Med. 2020 Oct 10;9(10):
pubmed: 33050427
Annu Rev Cell Dev Biol. 2004;20:781-810
pubmed: 15473860
Chem Biol Interact. 2013 Mar 25;203(1):287-91
pubmed: 23089045
Development. 2017 May 1;144(9):1712-1724
pubmed: 28348167
Am J Med Genet A. 2018 Jul;176(7):1594-1601
pubmed: 29704306